Global law firm Proskauer represented long-time client Celgene Corporation in its offering of three tranches of investment grade unsecured senior notes in an aggregate principal amount of $2.5 billion.
The three tranches comprise $500 million of 2.250% Senior Notes due 2019, $1 billion of 3.625% Senior Notes due 2024 and $1 billion of 4.625% Senior Notes due 2044. Bank of America Merrill Lynch, Credit Suisse Securities, Goldman, Sachs & Co., and Morgan Stanley & Co., acted as joint book-running managers and HSBC Securities acted as senior co-manager.
Proskauer has represented Celgene, one of the world’s largest biopharmaceutical companies, in all of its capital markets transactions since the company’s inception in 1986, including three previous senior notes offerings of $1.25 billion in 2010, $1.5 billion in 2012, and $1.5 billion in 2013.
The Proskauer team was led by Corporate partners Robert Cantone and Frank Lopez, and included partner Amanda Nussbaum (Tax) and associates Stephen Gruberg, Lily Desmond (Capital Markets), and Gary Silber (Tax).
